Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Amicus Therapeutics Raises USD4.7 Million in Venture Financing 12
Scioderm Raises USD20 Million in Series B Venture Financing 13
Callidus Biopharma Raises US$4.6 Million In Series A Financing 14
Scioderm Raises US$16 Million In Series A Financing 15
Scioderm Raises USD1 Million in Venture Financing 16
Partnerships 17
Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 17
Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 18
Licensing Agreements 19
Scioderm Plans To License Pharmaceuticals To Develop Topical Products 19
Equity Offering 20
Amicus Therapeutics Raises USD300 Million in Public Offering of Shares 20
Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 22
Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 24
Amicus Therapeutics Raises USD103.5 Million in Public Offering of Shares 26
Amicus Therapeutics Raises USD 40 Million in Public Offering 28
Amicus Therapeutics Completes Private Placement Of Securities For US$15 Million 29
Amicus Therapeutics Files Registration Statement For Public Offering Of Securities For US$145 Million 30
Amicus Therapeutics Raises USD18.6 Million in Private Placement of Shares 31
Amicus Therapeutics Completes Public Offering Of Common Stock For US$65 Million 32
Debt Offering 34
Amicus Therapeutics Raises USD250 Million in Private Placement of 3% Notes Due 2023 34
Amicus Therapeutics Announces Public Offering Of Debt Securities For US$25 Million 36
Acquisition 37
Amicus Therapeutics Acquires Celenex 37
Amicus Therapeutics Acquires MiaMed 38
Amicus Therapeutics Acquires Scioderm 39
Amicus Therapeutics Acquires Callidus Biopharma, Drug Discovery Company, For USD130 Million 41
Amicus Therapeutics Inc – Key Competitors 42
Amicus Therapeutics Inc – Key Employees 43
Amicus Therapeutics Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 46
Strategy And Business Planning 46
Sep 24, 2018: Amicus Therapeutics to buy Celenex for $100m upfront 46
Financial Announcements 47
Nov 05, 2018: Amicus Therapeutics announces third quarter 2018 financial results and corporate updates 47
Aug 07, 2018: Amicus Therapeutics announces second quarter 2018 financial results and corporate updates 49
May 08, 2018: Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates 51
Feb 28, 2018: Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates 53
Nov 08, 2017: Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates 55
Aug 07, 2017: Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates 58
May 09, 2017: Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates 60
Mar 01, 2017: Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates 62
Jan 09, 2017: Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance 64
Corporate Communications 66
Sep 11, 2018: Amicus Therapeutics appoints Lynn D. Bleil as Board Director 66
Jun 08, 2018: Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors 67
Product News 68
10/04/2017: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at World Muscle Society 68
09/10/2018: Amicus Therapeutics announces regulatory and clinical updates for AT-GAA in Pompe Disease 70
05/15/2017: Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study 71
02/07/2018: Amicus Therapeutics Announces Additional Positive Data in Pompe Disease Phase 1/2 Study at 14th Annual WORLDSymposium 73
01/22/2018: Amicus Therapeutics Announces Presentations and Posters at 14th Annual WORLDSymposium 2018 75
Product Approvals 77
Jun 26, 2018: Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease 77
Sep 21, 2017: U.S. FDA Grants Orphan Drug Designation for ATB200/AT2221 for Pompe Disease 79
Clinical Trials 80
Feb 15, 2017: Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium 2017 80
Other Significant Developments 81
Feb 27, 2018: Amicus Therapeutics Launches Healing Beyond Disease Initiatives to Change People’s Lives Living with Rare Diseases 81
Jan 08, 2018: Amicus Therapeutics Provides Full-Year 2018 Strategic Outlook and Financial Guidance 82
Appendix 84
Methodology 84
About GlobalData 84
Contact Us 84
Disclaimer 84
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amicus Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Amicus Therapeutics Raises USD4.7 Million in Venture Financing 12
Scioderm Raises USD20 Million in Series B Venture Financing 13
Callidus Biopharma Raises US$4.6 Million In Series A Financing 14
Scioderm Raises US$16 Million In Series A Financing 15
Scioderm Raises USD1 Million in Venture Financing 16
Amicus Therapeutics Enters into Research and Development Agreement with Perelman School of Medicine at the University of Pennsylvania 17
Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 18
Scioderm Plans To License Pharmaceuticals To Develop Topical Products 19
Amicus Therapeutics Raises USD300 Million in Public Offering of Shares 20
Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 22
Amicus Therapeutics Raises USD258.8 Million in Public Offering of Shares 24
Amicus Therapeutics Raises USD103.5 Million in Public Offering of Shares 26
Amicus Therapeutics Raises USD 40 Million in Public Offering 28
Amicus Therapeutics Completes Private Placement Of Securities For US$15 Million 29
Amicus Therapeutics Files Registration Statement For Public Offering Of Securities For US$145 Million 30
Amicus Therapeutics Raises USD18.6 Million in Private Placement of Shares 31
Amicus Therapeutics Completes Public Offering Of Common Stock For US$65 Million 32
Amicus Therapeutics Raises USD250 Million in Private Placement of 3% Notes Due 2023 34
Amicus Therapeutics Announces Public Offering Of Debt Securities For US$25 Million 36
Amicus Therapeutics Acquires Celenex 37
Amicus Therapeutics Acquires MiaMed 38
Amicus Therapeutics Acquires Scioderm 39
Amicus Therapeutics Acquires Callidus Biopharma, Drug Discovery Company, For USD130 Million 41
Amicus Therapeutics Inc, Key Competitors 42
Amicus Therapeutics Inc, Key Employees 43
Amicus Therapeutics Inc, Other Locations 44
Amicus Therapeutics Inc, Subsidiaries 44
List of Figures
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Amicus Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9